Ultrafine Particles in Human Lung Macrophages

Hauser, Russ; Godleski, John J.; Hatch, Victoria; Christiani, David C.
March 2001
Archives of Environmental Health;Mar/Apr 2001, Vol. 56 Issue 2, p150
Academic Journal
ABSTRACT. As knowledge about size dependency of particle toxicity continues to grow, attention has been focused on ultrafine particles (i.e., < 0.1 micro m in diameter). In recent studies with rats, investigators learned that ultrafine particles likely have greater pulmonary toxicity than larger particles, and it is possible that exposure to, and accumulation of, these particles in the human lung may be associated with adverse respiratory health effects. As part of an ongoing study, the authors performed bronchoalveolar lavage in 14 healthy current nonsmokers to investigate the extent to which ultrafine particles were present in lung macrophages. In addition, 10 of the 14 subjects performed pulmonary function tests. Eleven of the 14 subjects were utility workers, and 3 were nonmaintenance employees of a university. The authors used a Zeiss CEM902 electron microscope to study macrophages isolated from bronchoalveolar lavage fluid. Morphometric quantification revealed ultrafine particles in lung macrophages of all 14 volunteers; the average number of ultrafine particles/micro m[sup 3] cytoplasm per cell (UF[sub avg]) ranged from 34 to 231 (mean = 95, standard deviation = 54). Regression analysis showed that the UF[sub avg] was associated inversely with percent predicted forced expiratory volume in 1 second (FEV[sub 1.0]) (beta = -1.2 percent predicted FEV[sub 1.0]/10 ultrafine particles micro m[sup 3] cytoplasm per cell [standard error = 0.45, p = .03]). The demonstration of ultrafine particles in all 14 subjects, independent of occupational exposure, suggests that there is environmental exposure to ultrafine particles. The negative association between the number of ultrafine particles and ventilatory function demonstrates a need for further investigation into the pulmonary health effects of ultrafine particles.


Related Articles

  • Patients with COPD: do we fail them from beginning to end? Partridge, M.R. // Thorax;May2003, Vol. 58 Issue 5, p373 

    Editorial. Recognizes the burden of chronic obstructive pulmonary disease (COPD) to both the individual and the society. Development of a comprehensive approach for the prevention and control of respiratory disease; Importance of diagnosing COPD early in its natural history.

  • Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Mannino, D.M.; Buist, A.S.; Petty, T.L.; Enright, P.L.; Redd, S.C. // Thorax;May2003, Vol. 58 Issue 5, p388 

    Background: A study was undertaken to define the risk of death among a national cohort of US adults both with and without lung disease.Methods: Participants in the first National Health and Nutrition Examination Survey (NHANES I) followed for up to 22 years were...

  • Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Brusasco, V.; Hodder, R.; Miravitlles, M.; Korducki, L.; Towse, L.; Kesten, S. // Thorax;May2003, Vol. 58 Issue 5, p399 

    Background: A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos.Methods: Patients with COPD were enrolled in two 6-month randomised, placebo...

  • COPD: Management of Acute Exacerbation and Chronic Stable Disease. Hunter, Melissa H.; King, Dana E. // American Family Physician;8/15/2001, Vol. 64 Issue 4, p603 

    Acute exacerbations of chronic obstructive pulmonary disease (COPD) are treated with oxygen (in hypoxemic patients), inhaled beta2 agonists, inhaled anticholinergics, antibiotics and systemic corticosteroids. Methylxanthine therapy may be considered in patients who do not respond to other...

  • End-stage COPD. Fernandes, Tanya // Nursing Standard;10/10/2012, Vol. 27 Issue 6, p58 

    A quiz on end stage chronic obstructive pulmonary disease is presented.

  • Coping Behaviors of Individuals With Chronic Obstructive Pulmonary Disease. Chien-yun Wu; Yan-Yal Lee; Baig, Karin; Ora-anong Wichaikhum // MEDSURG Nursing;Dec2001, Vol. 10 Issue 6, p315 

    Presents a study which examined the coping behaviors of patients with chronic obstructive pulmonary disease. Methods; Results; Discussion.

  • Chronic obstructive pulmonary disease.  // Nursing Standard;1/30/2008, Vol. 22 Issue 21, p58 

    A quiz concerning chronic obstructive pulmonary disease is presented.

  • Authors' response to Young and Hopkins: vitamin D and lung function. Afzal, Shoaib; Lange, Peter; Bojesen, Stig E.; Freiberg, Jacob J.; Nordestgaard, Børge G. // Thorax;Aug2014, Vol. 69 Issue 8, p770 

    A response from the author of the article "Plasma 25 hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease" in the 2014 issue is presented.

  • Chronic Obstructive Pulmonary Disease Surveillance-- United States, 1971-2000. Mannino, David M.; Homa, David M.; Ford, Earl S.; Redd, Stephen C.; Akinbami, Lara J. // MMWR: Morbidity & Mortality Weekly Report;8/2/2002 Supplement, Vol. 51 Issue 30, p1 

    Presents data in the U.S. regarding chronic obstructive pulmonary disease (COPD) during the period between 1971 and 2000. COPD-associated activity and functional limitations between 1980 and 1996; Self-reported COPD prevalence; COPD physician office and hospital outpatient department visits.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics